TY - JOUR
T1 - Integrative epigenetic and gene expression analysis of renal tumor progression to metastasis
AU - Nam, Hye Young
AU - Chandrashekar, Darshan S.
AU - Kundu, Anirban
AU - Shelar, Sandeep
AU - Kho, Eun Young
AU - Sonpavde, Guru
AU - Naik, Gurudatta
AU - Ghatalia, Pooja
AU - Livi, Carolina B.
AU - Varambally, Sooryanarayana
AU - Sudarshan, Sunil
N1 - Publisher Copyright:
2018 American Association for Cancer Research.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - The Cancer Genome Atlas (TCGA) and other large-scale genomic data pipelines have been integral to the current understanding of the molecular events underlying renal cell carcinoma (RCC). These data networks have focused mostly on primary RCC, which often demonstrates indolent behavior. However, metastatic disease is the major cause of mortality associated with RCC and data sets examining metastatic tumors are sparse. Therefore, a more comprehensive analysis of gene expression and DNA methylome profiling of metastatic RCC in addition to primary RCC and normal kidney was performed. Integrative analysis of the methylome and transcriptome identified over 30 RCC-specific genes whose mRNA expression inversely correlated with promoter methylation, including several known targets of hypoxia inducible factors. Notably, genes encoding several metabolism-related proteins were identified as differentially regulated via methylation including hexokinase 2, aldolase C, stearoyl-CoA desaturase, and estrogen-related receptor-g (ESRRG), which has a known role in the regulation of nuclear-encoded mitochondrial metabolism genes. Several gene expression changes could portend prognosis in the TCGA cohort. Mechanistically, ESRRG loss occurs via DNA methylation and histone repressive silencing mediated by the polycomb repressor complex 2. Restoration of ESRRG in RCC lines suppresses migratory and invasive phenotypes independently of its canonical role in mitochondrial metabolism. Implications: Collectively, these data provide significant insight into the biology of aggressive RCC and demonstrate a novel role for DNA methylation in the promotion of HIF signaling and invasive phenotypes in renal cancer.
AB - The Cancer Genome Atlas (TCGA) and other large-scale genomic data pipelines have been integral to the current understanding of the molecular events underlying renal cell carcinoma (RCC). These data networks have focused mostly on primary RCC, which often demonstrates indolent behavior. However, metastatic disease is the major cause of mortality associated with RCC and data sets examining metastatic tumors are sparse. Therefore, a more comprehensive analysis of gene expression and DNA methylome profiling of metastatic RCC in addition to primary RCC and normal kidney was performed. Integrative analysis of the methylome and transcriptome identified over 30 RCC-specific genes whose mRNA expression inversely correlated with promoter methylation, including several known targets of hypoxia inducible factors. Notably, genes encoding several metabolism-related proteins were identified as differentially regulated via methylation including hexokinase 2, aldolase C, stearoyl-CoA desaturase, and estrogen-related receptor-g (ESRRG), which has a known role in the regulation of nuclear-encoded mitochondrial metabolism genes. Several gene expression changes could portend prognosis in the TCGA cohort. Mechanistically, ESRRG loss occurs via DNA methylation and histone repressive silencing mediated by the polycomb repressor complex 2. Restoration of ESRRG in RCC lines suppresses migratory and invasive phenotypes independently of its canonical role in mitochondrial metabolism. Implications: Collectively, these data provide significant insight into the biology of aggressive RCC and demonstrate a novel role for DNA methylation in the promotion of HIF signaling and invasive phenotypes in renal cancer.
KW - Disease Progression
KW - Epigenomics/methods
KW - Gene Expression Regulation, Neoplastic/genetics
KW - Humans
KW - Kidney Neoplasms/genetics
KW - Neoplasm Metastasis
UR - http://www.scopus.com/inward/record.url?scp=85059498775&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-17-0636
DO - 10.1158/1541-7786.MCR-17-0636
M3 - Article
C2 - 30131446
SN - 1541-7786
VL - 17
SP - 84
EP - 96
JO - Molecular Cancer Research
JF - Molecular Cancer Research
IS - 1
ER -